Yazici O, Sendur MAN, Ozdemir N, Aksoy S. Targeted therapies in gastric cancer and future perspectives. World J Gastroenterol 2016; 22(2): 471-489 [PMID: 26811601 DOI: 10.3748/wjg.v22.i2.471]
Corresponding Author of This Article
Sercan Aksoy, MD, Department of Medical Oncology, Hacettepe University Cancer Institute, Sihhiye, Ankara 06100, Turkey. saksoy07@yahoo.com
Research Domain of This Article
Oncology
Article-Type of This Article
Frontier
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 14, 2016; 22(2): 471-489 Published online Jan 14, 2016. doi: 10.3748/wjg.v22.i2.471
Targeted therapies in gastric cancer and future perspectives
Ozan Yazici, M Ali Nahit Sendur, Nuriye Ozdemir, Sercan Aksoy
Ozan Yazici, Nuriye Ozdemir, Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara 06100, Turkey
M Ali Nahit Sendur, Department of Medical Oncology, Yildirim Beyazit University, Ankara 06100, Turkey
Sercan Aksoy, Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara 06100, Turkey
Author contributions: Yazici O wrote the manuscript and was also involved in the editing process; Sendur MAN provided articles related to the issue and was also involved in editing the manuscript; Ozdemir N and Aksoy S analyzed the reports and selected the papers that were considered relevant for the aim of this review and was involved in editing of the manuscript.
Conflict-of-interest statement: Authors declare no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Sercan Aksoy, MD, Department of Medical Oncology, Hacettepe University Cancer Institute, Sihhiye, Ankara 06100, Turkey. saksoy07@yahoo.com
Telephone: +90-312-3052954 Fax: +90-312-3242009
Received: May 10, 2015 Peer-review started: May 12, 2015 First decision: September 11, 2015 Revised: October 5, 2015 Accepted: November 9, 2015 Article in press: November 9, 2015 Published online: January 14, 2016
Core Tip
Core tip: Trastuzumab was the first molecule shown to prolong both progression-free survival and overall survival in patients with advanced gastric cancer (AGC) when added to first-line chemotherapy in patients with AGC. In 2014, ramucirumab was approved as a single agent or in combination with paclitaxel for the treatment of patients with AGC. Many phase II-III clinical trials failed to showed activity of different targeted agents in patients with AGC. On the other hand, some molecules have shown promising activity in phase II trials and are expected to be in use in the coming years. Pertuzumab and c-Met pathway inhibitors have shown modest activity in a phase II trial. The results of two important ongoing phase III trials (JACOB and RILOMET-1) may change the recommendations for first-line treatment options in patients with AGC.
